Stay tuned — Roundtable takeaways will be published in Q3 2026!
Developed in collaboration with key opinion leaders across ISCT expert committees, the ISCT 2026 Dublin Roundtable Sessions provide an interactive forum for in-depth discussion and debate on pivotal topics shaping the future of cell and gene therapy.
This year’s roundtables will explore critical issues including iPSCs, exosomes, CAR-Ts, artificial intelligence, biomanufacturing innovation, and regulatory harmonization — bringing together global experts to share insights, identify sector-wide challenges, and co-develop actionable solutions.
Join us in Dublin to stay informed on emerging strategies, engage in meaningful dialogue that advances the CGT landscape, and build connections with peers and potential collaborators driving the field forward.
Scaling innovation with operational excellence.
Evaluate how MHRA guidelines frame opportunities and challenges for successful broad implementation of point-of-care manufacturing.
Of Interest To: Manufacturers, Therapy Developers, CDO/CDMO, Tools & Technologies Developers, Clinicians, CMC & Quality Professionals
Optimize manufacturing and commercialization strategies.
Of Interest To: Manufacturing, Commercial Strategy Leaders
Shaping the regulatory future of CGT.
Compare strategies for sourcing and managing raw materials when manufacturing CGT products across multiple jurisdictions.
Of Interest To: Regulators, Regulatory Professionals, Manufacturers, Therapy Developers, CDO/CDMO
Establish key opportunities to collect and leverage real-world data to inform CGT decision-making.
Of Interest To: Regulators, Policy Makers, Clinical Leaders
Access, adoption, and global market realities.
Address logistical hurdles and post-treatment complications for patients and healthcare systems.
Of Interest To: Regulatory Professionals, Regulators, Clinicians, Therapy Developers, Market Access Teams, Industry Leaders, Payers
Determine how the global CGT development pathway will evolve in response to the Most-Favored-Nation prescription drug pricing executive order.
Of Interest To: Market Access Leaders, Policy Experts, Commercial Strategy Teams
Sustainable pathways from science to scale.
Explore early development strategies to generate commercial viability beyond clinical success.
Of Interest To: Start-ups, Investors, Business Development, Manufacturers
Prioritize opportunities to implement AI to accelerate iPSC development.
Of Interest To: Manufacturing Leaders, Digital Transformation Teams, Investors
Technologies enabling the next generation of CGT.
Debate whether MSC-sEVs should be classified as a single drug entity or as a batch-specific therapeutic, and outline the implications of each approach.
Of Interest To: Clinicians, Researchers, Regulatory Experts